Page last updated: 2024-11-06

atamestane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

atamestane: aromatase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57050
CHEMBL ID2105987
SCHEMBL ID59128
MeSH IDM0140089

Synonyms (26)

Synonym
sh-489
biomed-777
atamestane
atamestano [spanish]
atamestane [inn]
atamestanum [latin]
1-methyl-1,4-androstadiene-3,17-dione
androsta-1,4-diene-3,17-dione, 1-methyl-
ccris 6528
1-methylandrosta-1,4-diene-3,17-dione
(8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione
62ga3k28b6 ,
atamestanum
96301-34-7
atamestano
unii-62ga3k28b6
CHEMBL2105987
SCHEMBL59128
atamestane [who-dd]
PEPMWUSGRKINHX-TXTPUJOMSA-N
1-methyl-androsta-1,4-diene-3,17-dione
1-methyl-androsta-1,4 -diene-3,17-dione
DB12194
Q4812727
(8r,9s,10s,13s,14s)-1,10,13-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3h-cyclopenta[a]phenanthrene-3,17(6h)-dione
DTXSID30869268

Research Excerpts

Overview

Atamestane is a potent competitive inhibitor of estrogen biosynthesis (aromatase) in several species, in vitro and in vivo. It has no endocrine side effects.

ExcerptReferenceRelevance
"Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. "( Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
el Etreby, MF; Habenicht, UF; Henderson, D; Nishino, Y,
)
3.02
"Atamestane is a potent competitive inhibitor of estrogen biosynthesis (aromatase) in several species, in vitro and in vivo, and has no endocrine side effects. "( Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
el Etreby, MF; Michna, H; Nishino, Y; Schneider, MR, 1989
)
1.94

Actions

ExcerptReferenceRelevance
"Atamestane caused an increase in LH levels, while no effect was observed with oral exemestane."( Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.
di Salle, E; Giudici, D; Ornati, G; Panzeri, A; Zaccheo, T, 1991
)
1.23

Treatment

ExcerptReferenceRelevance
"Treatment with atamestane (10 micromol/l) determined a strong inhibition of basal aromatase activity in both types of cells; however, its effect was markedly more pronounced in granulosa cells from normal ovary than in granulosa cells from polycystic ovaries (PCO; P < 0.01)."( Further evidence of increased aromatase activity in granulosa luteal cells from polycystic ovary.
Andreani, CL; Caruso, A; Cento, R; Lanzone, A; Lazzarin, N; Mancuso, S; Pierro, E, 1997
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (32.43)18.7374
1990's19 (51.35)18.2507
2000's6 (16.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.12 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (17.07%)5.53%
Reviews7 (17.07%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (65.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00097344]Phase 3842 participants Interventional2004-12-31Terminated(stopped due to Identical study Biomed 777-CLP-029 did not meet superiority endpoint)
Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00267553]Phase 3200 participants Interventional2005-11-30Terminated(stopped due to This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint)
Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer [NCT00010322]Phase 30 participants Interventional2000-10-31Terminated(stopped due to Withdrawn due to change in standard of care - new protocol required)
[NCT00044291]Phase 3865 participants (Actual)Interventional2002-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]